Ace Blend secured $9.91 million in Series A2 funding to prioritize clinical trials and product research over advertising. Founder Shivam Hingorani said, "We are putting science ahead of advertising." The nutrition startup reported 300% growth in FY26 and expects to reach profitability within the next 18 to 24 months.
Ace Blend plans to use its $9.91 million Series A2 funding round to invest in clinical trials, product-level research and quality testing rather than primarily buying advertising, Founder and Chief Vision Officer Shivam Hingorani told CNBC-TV18. The nutrition startup, which reported 300% growth in FY26, aims to generate evidence on nutrient absorption, shelf stability and long-term health impact. Hingorani said the company expects to achieve profitability in the next 18 to 24 months, after nine years of building the business.